Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis

PURPOSE: Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the safety and therapeutic activity of another immunomodulatory drug, pomalidomide...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Tefferi, Ayalew, Verstovsek, Srdan, Barosi, Giovanni, Passamonti, Francesco, Roboz, Gail J., Gisslinger, Heinz, Paquette, Ronald L., Cervantes, Francisco, Rivera, Candido E., Deeg, H. Joachim, Thiele, Juergen, Kvasnicka, Hans M., Vardiman, James W., Zhang, Yanming, Bekele, B. Nebiyou, Mesa, Ruben A., Gale, Robert P., Kantarjian, Hagop M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2009
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979191/
https://ncbi.nlm.nih.gov/pubmed/19652059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.7356
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak